IPSC — Century Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $200.29m
- $27.55m
- $2.24m
- 22
- 15
- 80
- 33
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 5.2 | 2.23 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 246 | 53.9 | 94.9 | 139 | 149 |
Operating Profit | -246 | -53.9 | -94.9 | -134 | -147 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -245 | -53.6 | -95.8 | -131 | -135 |
Provision for Income Taxes | |||||
Net Income After Taxes | -245 | -53.6 | -95.8 | -131 | -137 |
Net Income Before Extraordinary Items | |||||
Net Income | -245 | -53.6 | -95.8 | -131 | -137 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -245 | -53.6 | -95.8 | -131 | -137 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.53 | -6.53 | -2.96 | -2.09 | -2.04 |